A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer

F Lordick; EB Orra; A Cervantes; F Dayyani; C Rocha-Lima; R Greil; H van Laarhoven; S Lorenzen; R Kischel; K Shitara; J Chao

doi:10.1016/j.annonc.2020.04.158

A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer

F Lordick, EB Orra, A Cervantes, F Dayyani, C Rocha-Lima, R Greil, H van Laarhoven, S Lorenzen, R Kischel, K Shitara, J Chao

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	S114-S114
Journal	ANNALS OF ONCOLOGY
Volume	31
DOIs	https://doi.org/10.1016/j.annonc.2020.04.158
Publication status	Published - 2020
Event	ESMO 22nd World Congress on Gastrointestinal Cancer - ELECTR NETWORK Duration: 1 Jul 2020 → 4 Jul 2020

Access to Document

10.1016/j.annonc.2020.04.158

Cite this

Lordick, F., Orra, EB., Cervantes, A., Dayyani, F., Rocha-Lima, C., Greil, R., van Laarhoven, H., Lorenzen, S., Kischel, R., Shitara, K., & Chao, J. (2020). A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer. ANNALS OF ONCOLOGY , 31, S114-S114. https://doi.org/10.1016/j.annonc.2020.04.158

Lordick, F ; Orra, EB ; Cervantes, A et al. / A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer. In: ANNALS OF ONCOLOGY 2020 ; Vol. 31. pp. S114-S114.

@article{f983292b087c46229ddaab10001de995,

title = "A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer",

author = "F Lordick and EB Orra and A Cervantes and F Dayyani and C Rocha-Lima and R Greil and {van Laarhoven}, H and S Lorenzen and R Kischel and K Shitara and J Chao",

year = "2020",

doi = "10.1016/j.annonc.2020.04.158",

language = "English",

volume = "31",

pages = "S114--S114",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

note = "ESMO 22nd World Congress on Gastrointestinal Cancer ; Conference date: 01-07-2020 Through 04-07-2020",

}

Lordick, F, Orra, EB, Cervantes, A, Dayyani, F, Rocha-Lima, C, Greil, R, van Laarhoven, H, Lorenzen, S, Kischel, R, Shitara, K & Chao, J 2020, 'A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer', ANNALS OF ONCOLOGY , vol. 31, pp. S114-S114. https://doi.org/10.1016/j.annonc.2020.04.158

A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer. / Lordick, F; Orra, EB; Cervantes, A et al.
In: ANNALS OF ONCOLOGY , Vol. 31, 2020, p. S114-S114.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer

AU - Lordick, F

AU - Orra, EB

AU - Cervantes, A

AU - Dayyani, F

AU - Rocha-Lima, C

AU - Greil, R

AU - van Laarhoven, H

AU - Lorenzen, S

AU - Kischel, R

AU - Shitara, K

AU - Chao, J

PY - 2020

Y1 - 2020

U2 - 10.1016/j.annonc.2020.04.158

DO - 10.1016/j.annonc.2020.04.158

M3 - Abstract (Journal)

SN - 0923-7534

VL - 31

SP - S114-S114

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

T2 - ESMO 22nd World Congress on Gastrointestinal Cancer

Y2 - 1 July 2020 through 4 July 2020

ER -

Lordick F, Orra EB, Cervantes A, Dayyani F, Rocha-Lima C, Greil R et al. A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer. ANNALS OF ONCOLOGY . 2020;31:S114-S114. doi: 10.1016/j.annonc.2020.04.158